10-Q: Metagenomi Reports Wider Q2 Loss Amid Revenue Decline

Metagenomi, a precision genetic medicines company, reported a significantly wider net loss in the second quarter of 2025 due to a substantial decrease in collaboration revenue, primarily from the termination of its agreement with Moderna, despite progress in its genome editing pipeline.

Summary

• Net loss for the three months ended June 30, 2025, widened to $19.9 million, compared to $10.7 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, increased to $44.9 million, up from $35.9 million in the prior year period.
• Collaboration revenue decreased by $11.5 million to $8.5 million for the three months ended June 30, 2025, and by $18.5 million to $12.6 million for the six months ended June 30, 2025, primarily due to the termination of the Moderna Agreement.
• Research and development expenses decreased by $5.8 million to $22.5 million for the three months ended June 30, 2025, and by $12.1 million to $47.6 million for the six months ended June 30, 2025.
• General and administrative expenses decreased by $1.6 million to $7.0 million for the three months ended June 30, 2025, and by $3.5 million to $13.8 million for the six months ended June 30, 2025.
• Cash, cash equivalents, and available-for-sale marketable securities totaled $205.0 million as of June 30, 2025.
• Management estimates existing capital is sufficient to fund operations for at least the next 12 months from the filing date.
• The company established an At-The-Market (ATM) Sales Agreement for up to $75.0 million in common stock, with no shares sold as of June 30, 2025.

Sentiment

Score: 4

Explanation: The company reported a significantly wider net loss and a substantial decrease in collaboration revenue, primarily due to the termination of a key partnership. While R&D expenses decreased, the overall financial performance worsened. The lead program, MGX-001, faces potential delays in IND submission and may require further studies. An ongoing securities class action lawsuit adds legal and financial uncertainty. However, the company maintains a strong cash position for the next 12 months and continues to advance a promising pipeline with positive preclinical data across multiple programs and a robust technology platform, including advancements in AI-driven discovery and various gene editing systems. The establishment of an ATM program provides a mechanism for future capital raises.

Positives

• Achieved in vivo rodent proof-of-concept for all four Wave 1 genetic targets in collaboration with Ionis Pharmaceuticals in 2024, including transthyretin (TTR) for transthyretin amyloidosis and angiotensinogen (AGT) for refractory hypertension.
• Demonstrated durable and therapeutically relevant Factor VIII (FVIII) activity levels over approximately nineteen months in a non-human primate (NHP) study for MGX-001 (hemophilia A program).
• Bioengineered FVIII construct for MGX-001 demonstrated significantly higher FVIII activity levels in rodent and NHP studies, potentially enabling therapeutic levels at lower AAV doses and improved safety.
• Achieved in vivo proof-of-concept for Central Nervous System (CNS) editing with a single blood-brain-barrier penetrating AAV, a key milestone for neurological disorders.
• Novel Adenine Base Editors (ABEs) are potentially targetable to over 95% of the human genome's base pairs, a significantly wider range than first-generation SpCas9 base editors.
• ABE platform achieved greater than 90% editing efficiency simultaneously at seven genomic targets in primary T-cells with no detectable translocations or adverse effects on cell viability.
• Demonstrated first-ever targeted integration of over 900 base pairs in human cells with RIGS using all-RNA delivery.
• Achieved in vitro proof-of-concept for large gene integration using compact CRISPR-associated transposases (CAST) technology, publishing findings in Nature Communications in March 2025.
• Net cash used in operating activities decreased to $44.1 million for the six months ended June 30, 2025, from $56.2 million in the prior year period.
• Net cash provided by investing activities was $43.8 million for the six months ended June 30, 2025, compared to $107.8 million used in the prior year period, primarily due to net maturities of available-for-sale marketable securities.

Negatives

• Net loss for the three months ended June 30, 2025, widened to $19.9 million, from $10.7 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $44.9 million, from $35.9 million in the prior year period.
• Collaboration revenue decreased significantly by $11.5 million for the three months ended June 30, 2025, and by $18.5 million for the six months ended June 30, 2025, primarily due to the mutual termination of the Moderna Agreement.
• Incurred a $1.3 million loss related to the change in fair value of the long-term investment in Affini-T Therapeutics, Inc. during the three and six months ended June 30, 2025.
• Accumulated deficit reached $267.9 million as of June 30, 2025.
• The company expects to continue to incur substantial losses for the foreseeable future and may never achieve profitability.

Risks

• Incurred significant losses since inception and expects to incur losses for the foreseeable future, with no assurance of achieving or maintaining profitability.
• Operations require substantial additional funding; inability to raise capital could force delays, reductions, or termination of research and product development programs or commercialization efforts.
• Very early in development efforts, with no IND-enabling studies or clinical development initiated for any product candidate, implying many years before potential commercialization, if ever.
• Novel genome editing technology introduces additional development challenges and risks, including regulatory uncertainty, potential for unintended editing events, immunological reactions, and requirements for extended patient follow-up periods (e.g., FDA's recommended 15-year follow-up).
• The genome editing field is relatively new and rapidly evolving, with a possibility that other technologies may emerge with significant advantages.
• Uncertainty regarding obtaining and realizing benefits from regulatory designations (e.g., Fast Track, Breakthrough Therapy, RMAT, Rare Pediatric Disease PRV).
• Risk that FDA, EMA, or other regulatory authorities may not consider clinical trial endpoints to provide clinically meaningful results, making data analysis difficult.
• Conflicts with collaborators or strategic partners could lead to adverse actions or limit the company's ability to implement strategies.
• Collaborations may not be successful, impacting revenue generation from milestone or royalty payments.
• Commercial success depends on obtaining, maintaining, enforcing, and protecting intellectual property; insufficient breadth of protection could allow competitors to develop similar products.
• Difficulty and cost associated with protecting intellectual property and proprietary technologies.
• Currently subject to securities litigation (Vreeland v. Metagenomi Inc. et al.) alleging misleading statements regarding the Moderna collaboration, which is expensive and could divert management attention and result in substantial damages.
• Vulnerability to cyber-attacks, data privacy breaches, loss or leakage of data, and other disruptions, potentially leading to liability or adverse business effects.
• Unfavorable global economic conditions, including inflationary pressures, interest rate fluctuations, trade tariffs, and geopolitical tensions (e.g., Russia-Ukraine, Israel-Gaza, China-Taiwan), could adversely affect business.
• Risks related to health epidemics, pandemics, and other widespread outbreaks of contagious disease, which could significantly disrupt operations.
• Operations are vulnerable to interruption by disasters and terrorist activity.
• Challenges with properly managing the use of artificial intelligence (AI) and uncertainty regarding the legal landscape surrounding AI could result in reputational harm, competitive harm, and legal liability.
• Clinical trials may fail to demonstrate that product candidates are safe and effective, even after promising early preclinical results.
• Difficulty enrolling patients in future clinical trials, especially for rare genetically defined diseases.
• Manufacturing biologic products is complex and subject to product loss; reliance on third parties for manufacturing increases risks of insufficient quantities, unacceptable cost, or quality.
• Significant competition in a rapidly changing technological environment, with competitors potentially achieving regulatory approval sooner or developing safer/more effective therapies.
• Adverse public perception of genome editing and cellular therapy products may negatively impact demand or regulatory approval.
• Uncertainty related to pricing and reimbursement for novel, single-administration therapies.
• Inability to establish sales and marketing capabilities or enter into third-party agreements for these services.
• Disruptions at the FDA and other government agencies due to funding shortages, staffing reductions, or global health concerns could hinder timely development, approval, or commercialization.
• Changes in tax laws or their interpretation may adversely affect business and financial condition.
• Market price of common stock has been, and may continue to be, volatile.
• Future sales of common stock in the public market could cause stock price to fall.
• Insiders have substantial influence, potentially limiting stockholders' ability to affect key transactions.
• No dividends expected for the foreseeable future.
• Failure to establish and maintain proper and effective internal control over financial reporting could harm operating results.
• Bylaws designate specific courts as exclusive forum for certain litigation, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Provisions in corporate documents and Delaware law may have anti-takeover effects.
• Adverse developments affecting the financial services industry could impact business operations and financial condition.

Future Outlook

The company expects to continue incurring substantial losses for the foreseeable future as it advances its programs through preclinical and clinical development and incurs costs associated with operating as a public company. It anticipates needing additional funding beyond its current cash reserves to support ongoing research, develop and protect its intellectual property, further develop its platform, and hire additional personnel. Future funding will depend on factors such as the timing and progress of R&D, clinical trials, regulatory approvals, manufacturing costs, commercialization activities, intellectual property costs, and the ability to establish new collaborations. The company plans to conduct pre-IND and ex-U.S. regulatory meetings for MGX-001 in the second half of 2025 and submit IND and CTA submissions in 2026. It also aims to demonstrate NHP proof-of-concept for its lead secreted protein deficiency target in 2025 and nominate a development candidate in 2026. For the Ionis collaboration, the company plans to nominate one to two development candidates from Wave 1 targets and disclose the remaining two therapeutic indications in 2025, with IND-enabling activities for these candidates planned for 2026.

Management Comments

• Management believes that existing cash, cash equivalents and available-for-sale marketable securities as of June 30, 2025, of $205.0 million will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these unaudited condensed financial statements.
• While we have not received all of the data from the studies, we have commenced additional studies and may consider alternatives to this bioengineered FVIII construct.
• Based on the current information, we plan to conduct pre-IND and ex-U.S. regulatory meetings in the second half of 2025 and submit IND and clinical trial application (CTA) submissions in 2026.
• We plan to demonstrate NHP proof-of-concept for our lead secreted protein deficiency target in 2025 and nominate our development candidate in 2026.
• In partnership with Ionis, we plan to nominate one to two development candidates from the Wave 1 targets and disclose the remaining two therapeutic indications in 2025.
• In 2026, we plan to initiate IND-enabling activities for the development candidates nominated in 2025, and nominate additional development candidates from the remaining Wave 1 targets.
• To date, the macroeconomic trends discussed above have not had a material adverse impact on our business, financial condition or results of operations, but we continue to monitor these developments closely.
• We intend to defend vigorously against this litigation.

Industry Context

The company operates in the rapidly evolving precision gene editing and genetic medicines field, characterized by significant competition and a strong emphasis on intellectual property. It leverages metagenomics, AI, and high-throughput screening to discover novel genome editing tools, including programmable nucleases, base editors, and RNA/DNA-mediated integration systems (RIGS, CASTs). The industry is seeing advancements in gene therapy and gene editing, with only a limited number of products approved globally, highlighting the novel and high-risk nature of this space. The company's focus on in vivo gene editing for its wholly-owned pipeline and out-licensing for ex vivo cell therapy aligns with broader industry trends of specialized application of gene editing technologies. Macroeconomic factors and geopolitical tensions are noted as potential future risks, reflecting a cautious industry outlook.

Comparison to Industry Standards

• The company's lead program, MGX-001 for hemophilia A, differentiates from traditional gene therapies by aiming for stable Factor VIII (FVIII) expression through knock-in to a safe harbor location, contrasting with episomal delivery methods used by others, such as BioMarin Pharmaceutical Inc.'s Roctavian (valoctocogene roxaparvovec), which risk dilution and silencing.
• The company's novel Adenine Base Editors (ABEs) are stated to be potentially targetable to over 95% of the human genome's base pairs, a significantly wider range than first-generation SpCas9 base editors, suggesting a competitive advantage in targeting scope compared to companies like Beam Therapeutics or Verve Therapeutics, Inc.
• The achievement of in vivo proof-of-concept for Central Nervous System (CNS) editing with a single blood-brain-barrier penetrating AAV positions the company to address extrahepatic indications, a challenging area for gene editing, potentially competing with companies like Sarepta Therapeutics or Solid Biosciences in neuromuscular diseases.
• The company's compact CAST technology, demonstrating in vitro proof-of-concept for large gene integration (>10,000 bp), aims to overcome limitations of other gene editing systems in delivering large DNA templates, potentially offering an advantage over existing CRISPR/Cas systems from companies like CRISPR Therapeutics AG or Intellia Therapeutics, Inc.

Management Changes

Corporate Governance

Legal Proceedings

• A class action complaint, Vreeland v. Metagenomi Inc. et al., was filed on September 26, 2024, in the U.S. District Court for the Northern District of California.
• The lawsuit alleges violations of Section 11 and Section 15 of the Securities Act, claiming misleading statements and omissions concerning the company's collaboration with Moderna in its January and February 2024 registration statement and final prospectus materials.
• The plaintiffs seek compensatory damages, costs, and expenses, including attorneys' and expert fees.
• A motion to dismiss the claims was filed by all defendants on May 16, 2025, and is currently pending.
• The company is currently unable to predict the outcome or estimate a range of possible loss but intends to defend vigorously.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises (ATM program), volatility in stock price due to early-stage development and financial losses, and uncertainty from ongoing securities litigation. Potential for long-term value creation if pipeline programs succeed.
• Employees: Changes in management (CMO resignation), formation of new R&D committee, and ongoing stock-based compensation plans. Potential for job security concerns if funding is not secured or programs fail.
• Customers/Patients: Potential for new curative therapies for diseases like hemophilia A and cardiometabolic conditions if product candidates successfully navigate development and regulatory approval. Delays in development could impact patient access to novel treatments.
• Collaborators (Ionis, Affini-T): Continued collaboration on R&D programs, with milestone payments and potential royalties. The termination of the Moderna agreement highlights the risk of partnership changes.
• Creditors: Impacted by the company's ability to manage its accumulated deficit and secure future funding to meet financial obligations.

Next Steps

• Conduct pre-IND and ex-U.S. regulatory meetings for MGX-001 in the second half of 2025.
• Submit IND and clinical trial application (CTA) submissions for MGX-001 in 2026.
• Demonstrate NHP proof-of-concept for the lead secreted protein deficiency target in 2025.
• Nominate a development candidate for the lead secreted protein deficiency target in 2026.
• Nominate one to two development candidates from the Ionis Wave 1 targets and disclose the remaining two therapeutic indications in 2025.
• Initiate IND-enabling activities for the Ionis development candidates nominated in 2025 in 2026.
• Nominate additional development candidates from the remaining Ionis Wave 1 targets in 2026.
• Laurence Reid to be granted a one-time non-statutory stock option to purchase 42,000 shares of common stock on September 2, 2025.
• Continue to evaluate the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Expense Disaggregation Disclosures) on financial statements.

Key Dates

Recommendation

Metagenomi is an early-stage biotechnology company with a promising, yet high-risk, gene editing platform. The latest financial results show a significant widening of net loss and a substantial decline in collaboration revenue, primarily due to the termination of the Moderna agreement. This indicates a challenging financial period and increased reliance on its remaining collaborations and future capital raises. The delay in the IND submission for its lead program, MGX-001, and the need to explore alternatives for its FVIII construct, introduce further uncertainty and push out potential commercialization timelines. The ongoing securities class action lawsuit adds another layer of legal and financial risk. However, the company still holds a strong cash position for the next 12 months, and its technology platform continues to demonstrate robust preclinical progress across multiple programs (Ionis collaboration, CNS editing, ABEs, RIGS, CASTs). For a seasoned investor, the current financial performance and legal challenges warrant caution, but the underlying scientific advancements and pipeline potential suggest that exiting the position might be premature. A 'hold' recommendation reflects the balance between significant financial headwinds and the long-term, high-reward potential inherent in novel gene editing technologies, advising investors to monitor pipeline progress and financial stability closely.

Keywords

Genome Editing, Genetic Medicines, Biotechnology, CRISPR, Gene Therapy, Hemophilia A, Cardiometabolic Diseases, Precision Medicine, Drug Development, Preclinical Studies, Clinical Trials, SEC Filing, 10-Q, Financial Results, Biopharma, Rare Diseases, Orphan Drugs, Intellectual Property, Collaboration, AI in Biotech, Nucleases, Base Editors, RIGS, CAST systems, LNP Delivery, AAV Delivery